Maguire H C
Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Acta Derm Venereol. 1996 Jul;76(4):277-9. doi: 10.2340/0001555576277279.
Cyclophosphamide given before allergen and recombinant interleukin-12 administered at the time of allergic sensitization substantially increase the acquisition of allergic contact dermatitis in the mouse. Since their immunoadjuvant mechanisms appeared different, it seemed probable that combining cyclophosphamide pretreatment with interleukin 12 administration would result in a more intense allergic contact dermatitis than when either agent was used alone. This was tested in different groups of mice sensitized to dinitrofluorobenzene or to oxazolone. Consistently, immunopotentiation of allergic contact dermatitis was significantly greater with the two immunoadjuvants than with either alone. This immunoadjuvant combination is likely to find use in immunization protocols designed to induce a Th-1 helper cell response.
在变应原之前给予环磷酰胺，并在变应性致敏时给予重组白细胞介素-12，可显著增加小鼠变应性接触性皮炎的发生率。由于它们的免疫佐剂机制似乎不同，因此将环磷酰胺预处理与白细胞介素-12联合使用可能会导致比单独使用任何一种药物时更强烈的变应性接触性皮炎。在对二硝基氟苯或恶唑酮致敏的不同组小鼠中进行了此项测试。结果一致表明，两种免疫佐剂联合使用时对变应性接触性皮炎的免疫增强作用明显大于单独使用任何一种佐剂。这种免疫佐剂组合可能会在旨在诱导Th-1辅助细胞反应的免疫方案中得到应用。
